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etachronous  rectal  cancer  after  surgery  for
amilial adenomatous  polyposis:  what  should  we
xpect?amilial adenomatous polyposis (FAP) is an autosomal
ominant inherited syndrome characterized by multiple
denomatous polyps (predisposing to colorectal cancer devel-
pment) and numerous extra-colonic manifestations. It may
ffect up to 8 per 1000 persons. If not treated by prophylac-
ic colectomy, FAP patients will have an estimated 100% risk
f developing colorectal cancer (CRC). The majority of FAP
atients will be affected in a context of familial history. How-
ver, almost 30% may have a “de novo” mutation. Classic FAP
nd its attenuated form (AFAP) derive from germline APC (ade-
omatous polyposis coli) gene mutations.
In an ideal scenario, the majority (if not all) of FAP patients
hould undergo surgery as result of effective surveillance,
eing operated on while still asymptomatic. Therefore, the
ost important objective to be accomplished is CRC pre-
ention. Surgery represents the sole means of preventing
RC, through restorative proctocolectomy (RPC), or through
otal colectomy with ileorectal anastomosis (IRA). Apart from
bvious, it is widely known that RPC is associated with
ncreased early and late morbidity. On the other hand, it
s more  effective than IRA to prevent occurrence and mor-
ality from rectal cancer in patients with FAP undergoing
rophylactic surgery. Notwithstanding, making the choice
etween RPC and IRA continues a matter of debate. There-
ore, the paper published by Stevanato Filho et al. in the
resent issue of JCOL represents a very important contribu-
ion about deﬁning surgical options in FAP. In a retrospective
ingle-institutional analysis of 22 patients with classic FAP, the
uthors reported complications occurring in 34.3%, although
ith no mortality. Ultimately, the incidence of rectal cancer
fter RPC and after IRA was 2.3% and 18.8%, respectively. Given
hese results, what should be the expected CRC occurrence
or FAP patients undergoing surgery after genetic counsel-
ng and regular clinical follow-up? It should be warned that
 crude answer may not be available at the end of this
ditorial.IRA is currently recommended for patients with few rec-
tal polyps with high risk aversion and also for female patients
willing to be pregnant. IRA is associated with favorable surgical
and functional outcomes and a metachronous rectal cancer
rate of less than 15% in the post-RPC era.1,2 It is estimated
that after IRA, metachronous rectal cancer risk is associated
with the length of postoperative follow-up and the site of
APC mutation.3,4 It is also hypothesized that bad selection
criteria would account for a rate of metachronous rectal can-
cer after IRA above 15%. Nevertheless, maybe bad selection
criteria are not the major cause for a possibly high inci-
dence of rectal cancer after IRA. Perhaps, for a subgroup of
patients with manifest indications of IRA, it will be unfeasi-
ble to prevent the occurrence of metachronous rectal cancer
without additional information derived from mutation anal-
ysis. Maybe this is a reason why, during the last decades,
RPC progressively turned out to be the most common oper-
ation despite its surgical morbidity and need for technical
expertise.
It has been well established that there is a link between
the site of mutation of the APC gene and some features of the
phenotype of FAP. This is the so-called genotype–phenotype
correlation. What is the impact from mutation analysis on
surgical decision for FAP patients? In a study comprising
data from four national polyposis registries, according to
previously described genotype–phenotype correlations, 475
patients were divided into three genotype groups predicting
attenuated, intermediate, and severe polyposis phenotypes.5
In this study, the risks of proctectomy 20 years after prophy-
lactic colectomy were 10%, 39%, and 61% in the attenuated,
intermediate, and severe genotype groups, respectively. More-
over, risks of metachronous rectal cancer after colectomy were
3.7%, 9.3%, and 8.3%, respectively, in the three groups. It is
our view that mutation analysis resulted in a very acceptable
proﬁle of CRC prevention for patients with FAP undergo-
ing prophylactic colectomy and rectal preserving-surgery.
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However, how does this result compare to clinical decision
making without mutation analysis remains unknown. There-
fore, the results published by Stevanato Filho et al. in the
present issue may represent evidence toward a need for
broader use of genetics-based surgical decision. Unfortu-
nately, until there, mutation analysis will remain unavailable
to many  surgeons and institutions.
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